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A B S T R A C T
Purpose
Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was
to develop an expert consensus-driven working framework for comprehensive genetic evaluation of
inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically
informed management.
Methods
An expert consensus conference was convened including key stakeholders to address genetic
counseling and testing, PCA screening, and management informed by evidence review.
Results
Consensus was strong that patients should engage in shared decisionmaking for genetic testing.
There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for
suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected
Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening
discussions. BRCA2 achieved moderate consensus for factoring into early-stage management
discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement
was moderate to test all men with metastatic castration-resistant PCA, regardless of family
history, with stronger agreement to test BRCA1/2 andmoderate agreement to test ATM to inform
prognosis and targeted therapy.
Conclusion
To our knowledge, this is the ﬁrst comprehensive, multidisciplinary consensus statement to address
a genetic evaluation framework for inherited PCA in the multigene testing era. Future research
should focus on developing aworking deﬁnition of familial PCA for clinical genetic testing, expanding
understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for
PCA management, genetic testing of African American males, and addressing the value framework
of genetic evaluation and testing men at risk for PCA—a clinically heterogeneous disease.
J Clin Oncol 36:414-424. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer (PCA) is the third leading cause of
cancer-related death in US men, accounting for
26,730 deaths in 2017.1 There is increasing evidence
that PCA has substantial inherited predisposition,2,3
with higher risks conferred by BRCA2 and BRCA1
(associated with hereditary breast and ovarian
cancer [HBOC] syndrome), and HOXB13 (asso-
ciated with hereditary prostate cancer [HPC]).4-24
Furthermore, BRCA2 mutations have been asso-
ciated with poor PCA-speciﬁc outcomes.9-13 There
is also emerging evidence of the link between PCA
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and DNA mismatch repair (MMR) gene mutations (accounting for
Lynch syndrome [LS]).25-30 Furthermore, inherited genetic muta-
tions are being uncovered in up to 12% ofmenwith metastatic PCA,
primarily in DNA repair genes such as BRCA1, BRCA2, and
ATM,31,32 with improved clinical outcomes by speciﬁc targeted
agents.33,34 Identifying genetic mutations of inherited PCA, there-
fore, has implications for cancer risk assessment for men and their
families,35,36 for precision treatment of metastatic disease,33,34 and is
being incorporated into guidelines for individualized PCA screening
strategies speciﬁcally for male BRCA1/2 mutation carriers.35,37
However, no centralized guidelines exist regarding genetic
counseling and genetic testing for PCA or optimal use and in-
terpretation of multiple genes now available on commercial PCA
gene panels (Table 1).38 At least three commercial laboratories have
PCA multigene panels available that include BRCA1, BRCA2,
HOXB13, DNAMMR genes, and multiple additional genes (such
as ATM, CHEK2, andNBN; Table 1). Some of these genes provide
actionable PCA risk information, whereas data for PCA risk is
limited for other genes on these panels. Therefore, testing ca-
pability has created a dilemma regarding optimal application of
genetic tests for counseling and evaluation of inherited PCA.
Genetic counseling is a dynamic process in which trained
cancer genetic counseling professionals perform detailed intake of
personal history and family cancer history, discuss genetic in-
heritance of cancer and genetic test options, address implications
of genetic test results with patients and their families, and clarify
patient preferences regarding genetic testing to make an informed
decision for proceeding with testing.39,40 However, guidelines are
limited regarding genetic counseling and genetic testing for
PCA (Table 2) and focus only on BRCA1/2 testing. Current
National Comprehensive Cancer Network (NCCN)Genetic/Familial
High-Risk Assessment: Breast and Ovarian (Version 2.2017) guide-
lines address BRCA1/2 testing for menwith a personal history of PCA
limited to Gleason$ 7 and speciﬁc family history (FH) features.35 An
additional criterion for germline genetic testing is BRCA1/2mutation
detected on somatic tumor testing.35 Although these expert panel
guidelines begin to address BRCA1/2 testing for PCA, they exclude
addressing other genes now available through multigene panels,
several of which are implicated in PCA predisposition (Table 1).
Genetic testing has potential to inform PCA screening and
targeted treatment, as exempliﬁed in other cancers.35,36,41 NCCN
guidelines (Genetic/Familial High-Risk Assessment: Breast and
Ovarian) state that PCA screening should begin at age 45 years for
male BRCA2 mutation carriers and to consider this recommen-
dation for BRCA1 carriers.35 Current NCCN Prostate Cancer Early
Detection Panel (Version 2.2016) agreed that men should be asked
about the presence of known BRCA1/2 mutations in their fami-
lies.37 The group added consideration of FH of BRCA1/2mutations
to the baseline discussion of risks and beneﬁts of PCA screening
but believed that data are insufﬁcient to change screening and
biopsy recommendations.37 Given increasing knowledge of genetic
contribution to PCA (such as from HOXB13 and DNA MMR
genes) and expanding availability of commercial multigene panels
(Table 1), there is a need for enhanced guidance on how multigene
testing may be incorporated in PCA screening discussions.
Finally, precision medicine is catapulting the need for ge-
netic testing to inform cancer treatment, particularly in the
advanced-stage setting. Emerging studies report clinical activity
of polyadenosine diphosphate-ribose polyermerase (PARP) in-
hibitors in metastatic PCA, particularly for men with DNA repair
mutations.33,34 Recent accelerated US Food and Drug Admin-
istration approval of immune checkpoint inhibitors for microsatellite
instability-high and MMR-deﬁcient cancers further highlights the
increasing role of genetic testing in cancer treatment,42 with im-
plications for PCA. Thus, comprehensive guidance for multigene
testing for inherited PCA is now critical for cancer risk, screening,
and treatment implications.
Because multigene testing capability for PCA is now a reality,
a consensus conference was convened to address the clinical genetic
evaluation spectrum for inherited PCA. The Philadelphia Prostate
Cancer Consensus 2017 was held in Philadelphia, Pennsylvania on
March 3 and 4, 2017 and focused on the role of genetic testing for
inherited PCA risk as well as genetic counseling, screening, and
management on the basis of genetic ﬁndings. The conference was
attended by stakeholders involved in PCA early detection, treatment,
research, and patient advocacy. This was the ﬁrst centralized, mul-
tidisciplinary conference, to our knowledge, focused on addressing
and developing a working framework for the comprehensive genetic
evaluation of inherited PCA in the multigene testing era.
METHODS
Panel Members
The panel included 71 experts from the United States, Canada,
England, and the Netherlands. Panel selection criteria included consid-
eration of stakeholders with expertise in PCA early detection, treatment,
genetic counseling, clinical cancer genetics, research, bioethics, and ad-
vocacy, along with patient advocates (Appendix Table A1, online only).
Table 1. Current Genes on PCAMultigene Panels, Evidence Summary for PCA
Risk, and Guidelines Available
Gene Syndrome
Evidence Summary for
Association to PCA Risk*
Guidelines for PCA
Screening†
BRCA1 HBOC A x
BRCA2 HBOC A‡ x
DNA MMR
genes
LS B
HOXB13 HPC A
TP53 LFS D
ATM C
CHEK2 D
PALB2 D
NBN C
RAD51D D
NOTE. Adapted from Giri et al38 to include consensus panel review. Detailed
evidence review provided in Appendix Tables A2-A6.
Abbreviations: HBOC, hereditary breast and ovarian cancer; HPC, hereditary
prostate cancer; LFS, Li-Fraumeni syndrome; LS, Lynch syndrome; MMR,
mismatch repair; PCA, prostate cancer.
*Grade of evidence for PCA is summarized as follows: (A) High-grade evidence:
At least one prospectively designed study or three or more large validation
studies or three or more descriptive studies; (B) Moderate-grade evidence: two
cohort or case-control studies; (C) Emerging data: increasing data in support of
association to PCA, but not yet moderate-grade evidence; (D) Low/insufﬁcient:
limited data or not studied in the context of PCA.
†National Comprehensive Cancer Network High-Risk Assessment: Genetic/
Familial Breast and Ovarian (Version 2.2017).35
‡High-grade evidence for association to lethal/aggressive PCA.
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Consensus Model and Evidence Review
An expert opinion consensus model was used to address gaps in
evidence-based guidelines for multigene testing for PCA. A modiﬁed
Delphi model was followed, which incorporated elements of the Delphi
process and prior expert opinion consensus conferences relevant to cancer
risk and screening (Appendix Fig A1, online only).43,44 Literature was
provided to panel members ahead of the meeting, with initial presentations
focused on evidence review by experts. Grade of evidence was summarized
as follows, with grade designations adapted from prior literature and
consensusmodels44,45: (A) High-grade evidence: at least one prospectively-
designed study, or three or more large validation studies, or three or more
descriptive studies; (B) Moderate-grade evidence: two cohort or case-
control studies; (C) Emerging data: increasing data in support of asso-
ciation to PCA but not yet moderate-grade evidence; (D) Low/Insufﬁcient:
limited data or not studied in the context of PCA (Table 1; Appendix Tables
A2-A6, online only).
Development of Genetic Evaluation Framework
A conceptual framework was developed to address elements of ge-
netic evaluation, including genetic counseling and genetic testing criteria,
genes to test, and screening/management (Fig 1). FH criteria for genetic
testing focused on established hereditary cancer syndromes in which PCA
has been implicated, as well as broader FH to account for limitations in
obtaining detailed FH information.46,47 Genetic testing consensus dis-
cussions focused on genes currently included on commercially available
multigene panels (Table 1).
A series of questions were posed to address the genetic evaluation
framework (Fig 1). The following overarching questions were addressed:
(1)Which men should undergo genetic counseling and genetic testing
for PCA (Fig 1A)? Principles and elements of genetic counseling were
presented to panelists, including discussion of cancer genetics,
beneﬁts and limitations of genetic testing, ﬁnancial considerations,
implications for the patients and families, and genetic discrimination
laws.39,40 Ethical considerations of genetic testing and the need to
clarify patient preferences were also reviewed.48,49 Genetic testing
criteria were based on various personal cancer and FH features. FH
considerations included meeting established criteria for HBOC/LS/
HPC. Furthermore, considering limitations of obtaining accurate FH
information,46,47 these criteria included FH where at least two close
blood relatives have cancers in the HBOC/LS/HPC spectrum as per the
NCCNmodel.35,36 Finally, metastatic PCA and tumor sequencing were
speciﬁcally addressed.31,32 This consensus statement also developed
suggested genetic counseling referral criteria following the NCCN
model35,36 (Table 2).
(2)Which genes should be tested based on clinical and/or familial scenarios
(Fig 1B)? These questions focused on genes present on current PCA
multigene panels (Table 1; Appendix Tables A2-A6). Considerations
regarding personal history of PCA included Gleason score, stage, and
tumor sequencing results. FH considerations included meeting estab-
lished criteria for HBOC/LS/HPC or having at least two close blood
relatives with cancers in the HBOC/LS/HPC spectrum to address FH
limitations. Tumor sequencing results were also considered.
(3)How should genetic test results inform PCA screening (Fig 1C)? This
set of criteria focused on genes that inform PCA risk and may be
considered in PCA screening discussions. Risk for PCAwas reviewed
as well as association to aggressive PCA (Appendix Tables A2-A6).
Baseline age to check prostate-speciﬁc antigen (PSA) and interval to
screen based on genetic test results were adapted from other NCCN
guidelines.35,37 PCA screening guidelines by various professional
organizations were also reviewed.37,50-53 Finally, ongoing PCA
screening studies incorporating genetic status were summarized.54
Genetic Evaluation and Management
A
C
Elements of Criteria
      Meeting criteria for
         hereditary cancer
         syndromes
      Age at diagnosis
      Family history
      Metastatic disease
      Tumor sequencing
Which men
should undergo
genetic counseling
and genetic testing
for prostate cancer?
Which genes should be
tested based on
clinical/familial
scenarios?
Lab #1 Lab #2 Lab #3
ATM
BRCA1
MLH1
TP53
RAD51D
PMS2
NBN
PALB2
MSH6
MSH2
HOXB13
EPCAM
CHEK2
BRCA2
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Prostate cancer panels
B
How should genetic
test results inform
prostate cancer
screening?
Should genetic test
results inform
management of early-
stage/localized,
advanced/high-risk, or
metastatic castration-
resistant PCA?
D
Fig 1. Framework for genetic evaluation of
inherited prostate cancer (PCA).
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(4) Should genetic test results inform management of early-stage/localized,
advanced/high-risk, or metastatic, castration-resistant PCA (mCRPC;
Fig 1D)? These questions overall focused on genes on current PCA
multigene panels (Table 1) and if they should be factored into
management discussions with patients in the setting of early-stage/
localized disease, advanced/high-risk disease, or mCRPC. Evidence
for PCA aggressiveness was of primary consideration, which was
high grade for BRCA2, emerging for ATM, and limited for other
genes on multigene panels (Appendix Tables A2-A6). Genetically
informed treatments, such as PARP inhibition and immune
checkpoint inhibition, were also considered.33,34,42
Strength of Consensus
Votes were cast anonymously using an electronic audience response
system. Postconsensus reﬁnement process included readministering select
questions where there was debate among panelists. Strength of expert
opinion consensus was determined by percentage of agreement with an
answer choice: $ 75% for strong consensus, 50% to 74% for moderate
consensus, and , 50% for lack of consensus. Table 2 provides a com-
parison of current NCCN guidelines to consensus criteria and identiﬁes
the gaps in practice addressed by this consensus statement.
RESULTS
Evidence Review
Various studies were considered in review of evidence for
speciﬁc genes on multigene panels and PCA risk, including tumor
sequencing studies (Table 1; Appendix Tables A2-A6). Current
evidence linking BRCA1 and BRCA2 mutations to PCA risk was
considered high grade, with stronger association for BRCA2.
Furthermore, BRCA2 mutations are associated with poor PCA-
speciﬁc outcomes as well as poorer survival. Evidence linking
HOXB13mutations to PCAwas considered high grade. Evidence of
DNA MMR gene mutations to PCA risk was considered moderate
grade. Data regarding ATM and NBN mutations and PCA risk are
emerging in favor of association to PCA but are not yet at the level
of moderate grade at this time. Other genes on panels have low/
insufﬁcient data for PCA risk (Appendix Tables A2-A6).
Consensus Responses
Responses are summarized by overarching questions addressing
the genetic evaluation framework, focused on criteria that
garnered strong to moderate consensus supported by high- to
moderate-grade evidence (Table 2; Appendix Tables A2-A6).
Additional considerations are provided to add context to the
various criteria, to provide more details regarding discussion that
did not make the cutoff for consensus, and to add considerations
raised by panel members regarding need for additional discussion or
research.
(1) Which men should undergo genetic counseling and genetic
testing for prostate cancer (Fig 1A)?
Criteria. Men meeting any one of the following suggested
criteria should undergo genetic counseling and genetic testing:
• All menwith PCA from families meeting established testing or
syndromic criteria for the following:
s HBOC (Consensus: 93%)
s HPC (Consensus: 95%)
s LS (Consensus: 88%)
• Men with PCA with two or more close blood relatives on the
same side of the family with a cancer in the following syn-
dromes (broader FH):
s Postconsensus discussion included consideration of age
cutoff for this criterion. A speciﬁc age cutoff will require
additional data, and age at diagnosis is important to inquire
in the genetic counseling session with patients.
n HBOC (Consensus: 93%)
n HPC (Consensus: 86%)
n LS (Consensus: 86%)
• All men with mCRPC should consider genetic testing (Con-
sensus: 67%). Postconsensus discussion also included con-
sideration of testing men with metastatic, hormone-sensitive
PCA to identify germline mutations to inform potential future
treatment options and cascade testing in families.
• Men with tumor sequencing showing mutations in cancer-
risk genes should be recommended for germline testing,
particularly after factoring in additional personal history and
FH (Consensus: 77%).
Additional considerations. The consensus panel had strong
agreement that patients should engage in shared decision making
for genetic testing for PCA (Consensus: 77%). Suggested criteria to
refer men for genetic counseling included young age at PCA di-
agnosis (# 55 years) in the patient or a ﬁrst-degree relative, death
as a result of PCA in a ﬁrst-degree relative younger than 60 years, or
having FH suggestive of HBOC, HPC, or LS (Table 2). Additional
suggested referral criteria include tumor sequencing showing mu-
tations in hereditary cancer genes or metastatic disease (Table 2). The
panel achieved strong consensus that African American males should
follow the same criteria as males of other race groups until additional
genetic data in African American males are available (Consensus:
75%). Formales unaffectedwith PCA and no affectedmale relatives to
test, FH criteria similar to men with PCA would apply.
(2)Which genes should be tested based on clinical and/or familial
scenarios (Fig 1B)?
Criteria. Criteria with highest consensus are as follows:
• The following genes should be tested in males with PCA
meeting criteria for the corresponding syndrome:
s HOXB13 (Syndrome: HPC) (Consensus: 95%)
s BRCA1/BRCA2 (Syndrome: HBOC) (Consensus: 97%)
s DNA MMR genes (Syndrome: LS) (Consensus: 73%)
• The following genes may be tested in men with PCAwith two
or more close blood relatives on the same side of the family
with a cancer in the following hereditary cancer syndrome
spectra (broader FH):
s Postconsensus discussion included consideration of age
cutoff for this criterion. A speciﬁc age cutoff will require
further data, and age at diagnosis is important to inquire in
the genetic counseling session with patients.
n BRCA1/BRCA2 (HBOC cancer spectrum: breast, ovar-
ian, pancreatic, prostate cancers and melanoma)
(Consensus: 98%)
n DNA MMR genes (LS cancer spectrum: colorectal, en-
dometrial, upper GI tract, ovarian, pancreatic, and upper
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urinary tract cancers along with sebaceous adenocarci-
nomas) (Consensus: 97%). Postconsensus discussion
included the moderate nature of evidence of DNA MMR
genes and PCA risk, with suggestions to institute im-
munohistochemistry testing of prostate tumors for LS to
select men with greater chance of carrying a germline
DNA MMR mutation.
• Men with prostate tumor sequencing showing mutations in
the following cancer-risk genes should have conﬁrmatory
germline genetic testing for PCA predisposition: BRCA1/
BRCA2 (Consensus: 89%), DNA MMR genes (Consensus:
88%), HOXB13 (68%), ATM (61%).
• If men with mCRPC undergo genetic testing for treatment
determination, the following genes should be tested: BRCA1/2
(Consensus: 88%), ATM (Consensus: 62%).
(3) How should genetic test results inform PCA screening
(Fig 1C)?
Criteria. Criteria with highest consensus are as follows:
• BRCA2 mutation status should be factored into PCA
screening discussions (Consensus: 80%).
s Screening strategy:
n Baseline PSA at age 40 years or 10 years prior to youngest
PCA diagnosed in family (Consensus: 56%)
n Interval of screening yearly or determined by baseline PSA
(Consensus: 76%)
• HOXB13 mutation status should be factored into PCA
screening discussions (Consensus: 53%).
s Screening strategy:
n Baseline PSA at age 40 years or 10 years prior to youngest
PCA diagnosed in family (Consensus: 52%)
n Interval of screening yearly or determined by baseline PSA
(Consensus: 75%)
Additional considerations. Postconsensus opinion was to
consider a lower age limit to begin PSA screening, perhaps no
younger than 35 years. There was strong agreement to perform PSA
testing yearly or as dictated by the baseline PSA. This consensus aligns
with NCCN Breast and Ovarian guidelines35 but also expands on the
guideline to factor in age at diagnosis of an affectedmale with PCA in
the family for screening initiation as is modeled in colorectal cancer
guidelines.36 BRCA1 mutation status is part of the NCCN Breast
and Ovarian guidelines regarding consideration of baseline PSA
at age 45 years.35
(4) Should genetic test results inform management of early-
stage/localized PCA, advanced/high-risk PCA, and mCRPC (Fig
1D)?
Criteria. Criteria with highest consensus are as follows:
• BRCA2 mutation status should be factored into man-
agement discussion of early-stage/localized PCA: (Con-
sensus: 64%).
• BRCA2 (Consensus: 97%) and ATM (Consensus: 59%)
mutation status should be factored into management dis-
cussion of high-risk/advanced PCA.
• BRCA1 (Consensus: 83%), BRCA2 (Consensus: 88%), ATM
(Consensus: 56%) mutation status should be factored into
mCRPC treatment discussions.
DISCUSSION
To our knowledge, the Philadelphia Prostate Cancer Consensus 2017
was the ﬁrst attempt to garner expert opinion consensus on key areas
in the genetic evaluation continuum for inherited PCA. Increasing
scientiﬁc insights into the genetic predisposition to inherited PCA,
growing multigene testing capabilities, and limited guidelines ne-
cessitated expert consensus to address genetic counseling and
genetic testing, PCA screening, and management. This confer-
ence brought together key stakeholders in PCA treatment, ge-
netic counseling, research, and advocacy to consider the evidence
and develop a working framework for genetic counseling, genetic
testing, and management of inherited PCA in the multigene
testing era. Of particular note was the strong urologic repre-
sentation at this consensus.
The conference addressed critical gaps in guidelines relevant
to genetic evaluation for PCA. These gaps include consideration of
FH in cancer syndromes relevant to PCA, consideration of met-
astatic disease in multigene testing, tumor sequencing, and review
of genes on multigene panels for application of genetic testing to
PCA. Our conference focused on inherited PCA, which com-
plements a recent consensus conference that addressed germline
testing for advanced PCA as part of the overall proceedings.55
There was agreement in our consensus conference that men with
FH meeting strict criteria for HBOC, HPC, or LS and men having
FH of cancers in the spectrum of these cancer syndromes while not
meeting strict syndromic criteria (broader FH) can be considered
for genetic testing. This is an expansion on current NCCN High-
Risk Assessment: Breast and Ovarian guidelines,35 reﬂects the
growing evidence of genetic contribution to PCA beyond BRCA1
and BRCA2, and takes into account limitations of obtaining de-
tailed FH information that could affect meeting criteria for he-
reditary cancer syndromes.46,47
Genetic counseling for PCA will need focused development.
Overall, the genetic counseling model should include shared de-
cision making between provider and patient regarding genetic
testing. The discussion should clarify patient values and prefer-
ences related to screening, risk assessment, and treatment choice.
Counseling elements of genetic education; discussion of beneﬁts,
risks, and limitations of genetic testing for patients and families;
ﬁnancial implications; and genetic discrimination laws are also
important to discuss. Optimal delivery of pretest genetic coun-
seling to patients in the multigene testing era, particularly for
genetic testing for advanced/metastatic cancers for targetable
mutations, is an area under development. ASCO policy statement
2015 recognized the need for more research on delivery of pretest
counseling, particularly in the settings of multigene testing and
tumor sequencing, and emphasized the importance of patients to
receive genetic education and clarify patient preferences.56 Fur-
thermore, PCA germline multigene testing studies will help inform
counseling discussions of potential results from genetic testing.38 A
closer working relationship between PCA care providers, primary
care providers, and cancer genetics specialists will need to be
developed to address treatment and management needs while
providing patients with optimal genetic education and counseling.
Incorporating a genetic counseling and evaluation process into
a multidisciplinary PCA clinic setting is one approach.57
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The mCRPC setting is a unique area that will likely drive
a signiﬁcant proportion of genetic testing for PCA. With
emerging insights into targeted therapy for PCA33,34 and the
promise of immunotherapy in MMR-deﬁcient tumors,42,58
a greater percentage of patients with mCRPC will likely un-
dergo tumor sequencing to uncover targetable mutations,
which can have germline implications. The panel had moderate
agreement to test all men with mCRPC, which may be strengthened
pending future data of germline mutations and targeted agents in
mCRPC. Furthermore, some panelists raised questions on testing all
men with metastatic PCA and not limiting testing to the castration-
resistance setting. Because most of the current data on germline
mutations are in the castration-resistant setting,31-34 proposed
criteria were focused on mCRPC, which may change over time.
Postconsensus discussion also included the potential for broader
scope of genetic testing criteria in the treatment setting versus the
risk-assessment setting, which can be considered in future consensus
updates. Greater information from this population regarding FH,
age at diagnosis, and germline mutation spectrumwill be crucial
to advance and reﬁne the understanding of genetic predisposition
to lethal PCA.
Cost effectiveness of genetic testing for inherited PCA is an
important consideration. Our consensus statement outlines tar-
geted testing for selected individuals (in contrast to population-
based screening) and is consistent with strategies for hereditary
breast cancer testing of BRCA1/2. Research has shown that such
targeted hereditary testing for a prevalent disease like breast cancer
is cost effective under several different economic scenarios when
directed at those at highest risk of carrying a mutation.59-62 For
PCA, there is a need to build on the ﬁndings of these studies and
model survival and quality-adjusted life-years for patients who are
at high risk versus those at population risk for PCA. Thus, as we
deﬁne who should undergo genetic counseling and testing for
inherited PCA, we also call for renewed emphasis on the economic
evaluation of different strategies to promote patient-centric, high-
value genetic evaluation and cancer care.
There are some limitations to consider. Grading of evi-
dence was based on prior consensus conferences, with a noted
need for a greater evidence base to inform future criteria de-
velopment. Our objective was to address the application of
multigene testing for PCA through consensus review of existing
literature and develop a genetic evaluation framework that can
be modiﬁed in the future. Another consideration is that the
panel consisted of experts and stakeholders engaged in PCA
genetics, research, treatment, and advocacy, which may have
affected agreement due to breadth of expertise. However,
a strength of the consensus was the broad input from thought
leaders in various disciplines engaged with PCA, which pro-
vided balanced views toward criteria development. The con-
sensus highlighted key areas in need of research, including
developing a working deﬁnition of HPC in a clinical setting,
expanding insights into genetic contribution to aggressive/lethal
PCA, developing genetic counseling and referral strategies that
engage urologists and primary care providers, addressing the
urgent need for focused studies of genetic testing for African
American males, evaluating clinical use of genetic testing in PCA
screening and management, and expanding health services re-
search for optimized delivery of genetic education to broader
populations.
Overall, this consensus conference was a ﬁrst step to un-
derstand the issues confronting application of genetic testing to
PCA and develop a meaningful framework using the best ev-
idence available. The need to revise and optimize consensus
criteria is noted, based on the dynamic nature of knowledge
and progress in this ﬁeld. Several consensus panel members
are also members of NCCN guidelines panels, which may lead
to consideration of consensus review and criteria for in-
corporation into respective NCCN guidelines regarding ge-
netic testing for inherited PCA. NCCN Prostate Cancer Early
Detection guidelines will likely include stronger consideration
of BRCA mutation status in PCA screening discussions and
may consider this consensus statement in future guideline
updates.
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Table A1. Consensus Conference Panel Members
Panel Member Institution Specialty
Wassim Abida, MD, PhD Memorial Sloan Kettering Cancer Center Medical Oncology
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Amie Blanco, MS, LCGC UCSF Helen Diller Family Comprehensive Cancer Center Genetic Counseling
John Buehler N/A Patient Advocate
Arthur “Bud” Burnett, MD, MBA Johns Hopkins Medical Institutions Urology
William J. Catalona, MD Northwestern University, Feinberg School of Medicine; R.H.
Lurie Comprehensive Cancer Center
Urology
Robin Cole N/A Patient Advocate
Kathleen A. Cooney, MD University of Utah School of Medicine Medical Oncology/Genetics
Matthew Cooperberg, MD, MPH UCSF Helen Diller Family Comprehensive Cancer Center Urology
E. David Crawford, MD University of Colorado, Denver Urology
Robert B. Den, MD Jefferson Sidney Kimmel Cancer Center Radiation Oncology
Adam P. Dicker, MD, PhD Jefferson Sidney Kimmel Cancer Center Radiation Oncology
Scott Eggener, MD University of Chicago Urology
Neil Fleshner, MD University of Toronto, Princess Margaret Cancer Centre Urology
Matthew L. Freedman, MD Harvard Medical School/Dana-Farber Cancer Institute Medical Oncology/Genetics
Veda N. Giri, MD Jefferson Sidney Kimmel Cancer Center Medical Oncology/Clinical Cancer Genetics
Leonard G. Gomella, MD Jefferson Sidney Kimmel Cancer Center Urology
Freddie C. Hamdy, FRCS, FMedSci University of Oxford, Oxford England Urology
Jean Hoffman-Censits, MD Jefferson Sidney Kimmel Cancer Center Medical Oncology
Mark D. Hurwitz, MD Jefferson Sidney Kimmel Cancer Center Radiation Oncology
Colette Hyatt, MS, LCGC Jefferson Sidney Kimmel Cancer Center Genetic Counseling
William B. Isaacs, PhD Johns Hopkins Medical Institutions Genetics Research
Christopher J. Kane, MD University of California San Diego Urology
Philip Kantoff, MD Memorial Sloan Kettering Cancer Center Medical Oncology
R. Jeffrey Karnes, MD Mayo Clinic, Rochester Urology
Lawrence I. Karsh, MD The Urology Center of Colorado Urology
Peter Kaye, Sr N/A Patient Advocate
Wm. Kevin Kelly, DO Jefferson Sidney Kimmel Cancer Center Medical Oncology
Eric A. Klein, MD Cleveland Clinic Urology
Karen E. Knudsen, PhD Jefferson Sidney Kimmel Cancer Center Oncology Research
Daniel W. Lin, MD University of Washington Urology
Kevin R. Loughlin, MD, MBA Brigham and Women’s Hospital, Harvard Medical School Urology
Grace Lu-Yao, PhD Jefferson Sidney Kimmel Cancer Center Population Science
S. Bruce Malkowicz, MD University of Pennsylvania Urology
Mark J. Mann, MD Jefferson Sidney Kimmel Cancer Center Urology
J. Ryan Mark, MD Jefferson Sidney Kimmel Cancer Center Urology
Peter A. McCue, MD Jefferson Sidney Kimmel Cancer Center Pathology
Martin M. Miner, MD Brown University Primary Care
Todd Morgan, MD University of Michigan Urology
Judd W. Moul, MD Duke University, Duke Cancer Institute Urology
Ronald E. Myers, PhD Jefferson Sidney Kimmel Cancer Center Medical Decision Making
Research/Population Science
Sarah M. Nielsen, MS, CGC The University of Chicago Genetic Counseling
Elias Obeid, MD, MPH Fox Chase Cancer Center Medical Oncology/Genetics
Christian P. Pavlovich, MD Johns Hopkins Medical Institutions Urology
Stephen C. Peiper, MD Jefferson Sidney Kimmel Cancer Center Pathology
David F. Penson, MD, MPH Vanderbilt University Medical Center Urology
Daniel Petrylak, MD Yale University Medical Oncology
Curtis A. Pettaway, MD The University of Texas MD Anderson Cancer Center Urology
Robert Pilarski, MS, LGC, MSW The Ohio State University Genetic Counseling
Peter A. Pinto, MD National Cancer Institute Urology
Wendy Poage, MHA Prostate Conditions Education Council Prostate Cancer Education/Advocacy
Ganesh V. Raj, MD, PhD University of Texas Southwestern Medical Center at Dallas Urology
Timothy R. Rebbeck, PhD Dana Farber Cancer Institute and Harvard TH Chan School of
Public Health
Genetics Research
Mark E. Robson, MD Memorial Sloan Kettering Cancer Center Breast Oncology/Genetics
Matt T. Rosenberg, MD Mid-Michigan Health Center Primary Care
Howard Sandler, MD, MS Cedars-Sinai Medical Center Radiation Oncology
Oliver Sartor, MD Tulane University Medical School Medical Oncology
Edward “Ted” Schaeffer, MD, PhD Northwestern University, Feinberg School of Medicine; R.H.
Lurie Comprehensive Cancer Center
Urology
Gordon F. Schwartz, MD Foundation for Breast and Prostate Health Breast Surgery
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The following series of tables highlight the studies referenced by the consensus panel concerning grade of evidence for prostate
cancer (PCA) risk by genes on PCA multigene panels. Grade of evidence is provided in the titles of Tables A2-A6. (A) High-grade
evidence: At least one prospectively designed study or three or more large validation studies or three or more descriptive studies;
(B) Moderate-grade evidence: two cohort or case-control studies; (C) Emerging data: increasing data in support of association to
PCA, but not yet moderate-grade evidence; (D) Low/insufﬁcient: limited data or not studied in the context of PCA.
Table A2. Case Series of BRCA1 and BRCA2 and PCA Risk [BRCA1 and BRCA2 (Evidence: A)]
First Author Population PCA Risk (BRCA1) PCA Risk (BRCA2) Comments
BCLC1 BCLC included 173 BRCA2- linked or
mutation-positive families (3,728
individuals and 333 cancers*)
Not assessed Overall: RR, 4.65 (95% CI,
3.48 to 6.22)
Men younger than 65 years: RR, 7.33; 95%
CI, 4.66 to 11.52
Thompson2 BCLC family set that included 7,106
women and 4,741 men, among whom
2,245 were carriers of BRCA1
mutations, 1,106 were tested
noncarriers, and 8,496 were not tested
Overall: RR, 1.07 (95% CI,
0.75 to 1.54)
Not assessed Men younger than 65 years: RR, 1.82; 95%
CI, 1.01 to 3.29
Mersch3 Clinical genetics population at a single
institution from 1997-2013. Compared
cancer incidence to US Statistics Report
by CDC for general population cancer
incidence
SIR, 3.809 (95% CI, 0.766
to 11.13)
SIR, 4.89 (95% CI, 1.959 to
10.075)
Agalliu4 290 men (white, n = 257; African
American, n = 33) diagnosed with PCA
at younger than 55 years and
unselected for family history
Not assessed RR, 7.8 (95% CI, 1.8 to 9.4)
Kote-Jarai5 1,832 men diagnosed with PCA between
age 36 and 88 years who participated in
the UK Genetic Prostate Cancer Study
Not assessed RR, 8.6 (95% CI, 5.1 to
12.6)
MLPA was not used; therefore, the
mutation frequency may be an
underestimate, given the inability to
detect large genomic rearrangements.
Leongamornlert6 913 men with PCA who participated in the
UK Genetic Prostate Cancer Study;
included 821 cases diagnosed between
age 36 and 65 years, regardless of
family history, and 92 cases diagnosed
at older than 65 years with a family
history of PCA
RR, 3.75 (95% CI, 1.02 to
9.6)
Not assessed
NOTE. Adapted from the National Cancer Institute PDQ Genetics of Prostate Cancer Summary.7
Abbreviations: BCLC, Breast Cancer Linkage Consortium; CDC, Centers for Disease Control and Prevention; MLPA, multiplex ligation-dependent probe ampliﬁcation;
PCA, prostate cancer; RR, relative risk; SIR, standardized incidence ratio.
*Includes all cancers except breast, ovarian, and nonmelanoma skin cancers.
Table A1. Consensus Conference Panel Members (continued)
Panel Member Institution Specialty
Mark S. Shahin, MD Hanjani Institute for Gynecologic Oncology; Abington Hospital-
Jefferson Health
Gynecologic Oncology
Neal D. Shore, MD Atlantic Urology Clinics/Carolina Urologic Research Center Urology
Brian Shuch, MD Yale University Urology
Howard R. Soule, PhD Prostate Cancer Foundation Basic and Clinical Research
Scott A. Tomlins, MD, PhD University of Michigan Medical School Pathology
Edouard J. Trabulsi, MD Jefferson Sidney Kimmel Cancer Center Urology
Robert Uzzo, MD Fox Chase Cancer Center Urology
Donald J. Vander Griend, PhD The University of Chicago Basic and Clinical Research
Patrick C. Walsh, MD Johns Hopkins Medical Institutions Urology
Carol J. Weil, JD National Cancer Institute Bioethics
Richard Wender, MD American Cancer Society Family and Community Medicine
NOTE. Additional manuscript contributors: Gerald L. Andriole, MD (Washington University School of Medicine; Urology); Justin E. Bekelman, MD (University of
Pennsylvania Perelman School of Medicine; Radiation Oncology and Medical Ethics and Health Policy).
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Table A3. Case-Control Studies of BRCA1 and BRCA2 and Survival Outcomes (Evidence: A for BRCA2 )
First Author Cases Controls PCA-Speciﬁc Survival Overall Survival Comments
Tryggvado´ttir8 30 men diagnosed with
PCA who were carriers
of BRCA2 999del5
founder mutation
(Icelandic population)
59 men with PCA matched
by birth and diagnosis
year and conﬁrmed not
to carry the BRCA2
999del5 mutation
BRCA2 999del5 mutation
was associated with
a higher risk of death from
PCA (HR, 3.42; 95% CI,
2.12 to 5.51), which
remained after adjustment
for tumor stage and grade
(HR, 2.35; 95% CI, 1.08 to
5.11).
Not assessed
Edwards9 21 men diagnosed with
PCA who harbored
a BRCA2 mutation: six
with early-onset disease
(# 55 years) from
a United Kingdom PCA
study and 15 unselected
for age at diagnosis from
a United Kingdom clinical
series
1,587 age- and stage-
matched men with PCA
Not assessed Overall survival was lower in
carriers of BRCA2
mutations (4.8 years) than
in noncarriers (8.5 years);
HR, 2.14 (95% CI, 1.28 to
3.56; P = .003).
Gallagher10 832 AJ men diagnosed
with localized PCA
between 1988 and 2007,
of whom there were six
carriers of BRCA1
mutations and 20
carriers of BRCA2
mutations
454 AJ men with no history
of cancer
After adjusting for stage,
PSA, Gleason score, and
therapy received:
Not assessed The BRCA1 5382insC
founder pathogenic
variant was not tested in
this series.– Carriers of BRCA1
185delAG mutation had
a greater risk of death as
a result of PCA (HR, 5.16;
95% CI, 1.09 to 24.53;
P = .001).
–Carriers of BRCA2
6174delT mutation had
a greater risk of death as
a result of PCA (HR, 5.48;
95% CI, 2.03 to 14.79;
P = .001).
Thorne11 40 men diagnosed with
PCA who were carriers
of BRCA2 mutations
from 30 familial breast
cancer families from
Australia and New
Zealand
97 men from 89 familial
breast cancer families
from Australia and New
Zealand with PCA and no
BRCA mutation found in
the family
BRCA2 carriers had
increased risk of PCA-
speciﬁc mortality (HR, 4.5;
95% CI, 2.12 to 9.52; P ,
.001), compared with
noncarrier
BRCA2 had increased risk of
death (HR, 3.12; 95% CI,
1.64 to 6.14; P , .001),
compared with noncarriers
There were too few BRCA1
carriers available to
include in the analysis.
Castro12 2,019 men diagnosed with
PCA from the United
Kingdom, of whom 18
were carriers of BRCA1
mutations and 61 were
carriers of BRCA2
mutations
1,940 men who were
BRCA1/2 noncarriers
PCA-speciﬁc survival at 5
years:
Overall survival at 5 years: For localized PCA,
metastasis-free survival
was also higher in
controls than in mutation
carriers (93% v 77%;
HR, 2.7).
– BRCA1: 80.8% (95% CI,
56.9% to 100%)
– BRCA1: 82.5% (95% CI,
60.4% to 100%)
– BRCA2 : 67.9% (95% CI
,53.4% to 82.4%; P ,
.001)
– BRCA2: 57.9% (95% CI,
43.4% to 72.4%; P ,
.001)
– Controls: 90.6% (95% CI,
88.8% to 92.4%; P, .001)
– Controls: 86.4% (95% CI,
84.4% to 88.4%; P ,
.001)
Castro13 1,302 men from the United
Kingdom with local or
locally advanced PCA,
including 67 carriers of
BRCA1/2 mutations
1,235 men who were
BRCA1/2 noncarriers
PCA-speciﬁc survival: Not assessed Multivariate analysis
conﬁrmed BRCA
mutations as an
independent prognostic
factor for cause-speciﬁc
survival: (HR, 2.17; 95%
CI, 1.16 to 4.07; P = .016)
– BRCA1/2: 61% at 10
years
– Noncarriers: 85% at 10
years
NOTES. Adapted from the National Cancer Institute PDQ Genetics of Prostate Cancer Summary.7 Rates of BRCA1/BRCA2mutations in metastatic PCA described in the paper.
Abbreviations: AJ, Ashkenazi Jewish; HR, hazard ratio; PCA, prostate cancer; PSA, prostate-speciﬁc antigen.
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Table A4. HOXB13 (G84E) and Association to PCA Risk (Evidence: A)
First Author Cases Controls OR of PCA Risk
Ewing14 94 unrelated patients from hereditary PCA
families; four probands carried G84E
mutation. Conﬁrmation: 5,083 PCA cases
(combination of hereditary, familial, early-
onset, or localized PCA cases)
1,401 screened controls Menwith a positive family history of PCA: 2.2%
v negative: 0.8% (OR, 2.8; 95%CI, 1.6 to 5.1;
P , .001)
Men younger than 55 years at diagnosis: 2.2%
v older than 55 years: 0.8% (OR, 2.7; 95%CI,
1.6 to 4.7; P , .001)
Men with a positive family history of PCA and
younger than 55 years at diagnosis: 3.1% v
a negative family history of PCA and age at
diagnosis older than 55 years: 0.6% (OR, 5.1;
95% CI, 2.4 to 12.2; P , .001)
Control subjects: 0.1%-0.2%
Xu15 2,443 PCA families from ICPCG. Among carrier
families, cases included 382 men with PCA.
2,443 PCA families from ICPCG; among carrier
families, controls included 137 men without
PCA
OR, 4.42; 95% CI, 2.56 to 7.64
Akbari16 1,843 cases with PCA 2,225 control men without PCA 5.8; 95% CI, 1.3 to 26.5; P = .01
Breyer17 928 familial PCA probands 930 controls without personal or family history
of PCA
7.9; 95% CI, 1.8 to 34.5; P = .0062; carrier rate
was 1.9% among all familial case probands
and 2.7% among probands of pedigrees with
three or more affected with PCA.
Karlsson18 5,003 population-based cases in Sweden
(CAPS and Stockholm-1 studies)
4,693 population-based controls in Sweden
(CAPS and Stockholm-1 studies)
CAPS: OR, 3.4; 95% CI, 2.2 to 5.4;
Stockholm-1: OR, 3.5; 95% CI, 2.4 to 5.2
Young-onset: OR, 8.6; 95% CI, 5.1 to 14.0
Hereditary PCA: OR, 6.6; 95% CI, 3.3 to 12.0
Kluzniak19 3,515 patients with PCA in Poland 2,604 controls in Poland OR, 5.0; 95% CI, 1.5 to 16.7; P = .008
Familial PCA: OR, 8.4; 95% CI, 1.9 to 37.7;
P = .005
Laitinen20 4,000 PCA cases in Finland 5,000 controls in Finland All cases and controls: OR, 7.1; 95% CI, 5.5 to
9.3
Hereditary PCA: OR, 8.8; 95% CI, 4.9 to 15.7
Stott-Miller21 1,310 population-based PCA cases from Seattle
region
1,259 age-matched controls Overall: OR, 3.3; 95% CI, 1.21 to 8.96
Gudmundsson22 9,988 PCA cases in Iceland, Chicago, Spain,
Netherlands, Romania, United Kingdom
61,994 controls in Iceland, Chicago, Spain,
Netherlands, Romania, United Kingdom
OR, 7.1; 95% CI, 4.62 to 10.78; Pcomb , .001
Witte23 Family-based PCA study (647 cases);
aggressive incident PCA (998 cases)
Family-based PCA study (477 controls);
aggressiveness study (542 controls)
OR, 4.8; P = .01
Abbreviations: CAPS, Cancer of the Prostate in Sweden; ICPCG, International Consortium of Prostate Cancer Genetics; OR: odds ratio; PCA, prostate cancer; P_comb,
combined P value.
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Table A5. DNA MMR Genes, PCA Risk, and Molecular Data (Evidence: B)
First Author Population Results Comments
Grindedal24 106 male DNA MMR mutation carriers from
Norwegian Cancer Registry
Expected number of PCAs was 1.52 compared
with nine observed (P , .01).
Loss of MMR gene expression was found in
seven of eight tumors.
Mean age of onset of PCA was 60.4 years
compared with 66.6 expected (P = .006).
No. of men with Gleason score between 8 and
10 was signiﬁcantly higher than expected
(P , .001).
Haraldsdottir25 Compared rates of PCA from Lynch syndrome
families at academic institution to general
population rates of PCA in SEER
PCA was observed in 11 of 188 males with Lynch
syndrome.
Impaired MMR expression and microsatellite
instability were seen in one out of two PCA
specimens available for testing.SIR, 4.87; 95% CI, 2.43 to 8.71
Bauer26 95 individuals were identiﬁed as members of
potential Lynch syndrome families from
a hereditary PCA study; underwent radical
prostatectomy and 35 tumors from 31
families underwent MSI analysis.
Two of 35 prostate tumors were MSI high,
suggestive of germline DNA MMR mutation.
One patient had IHC loss that correlated with
germline MMR mutation.
Raymond27 Two family cancer registries for total of 198
Lynch syndrome families
Cumulative lifetime risk of PCA (to age 80 years)
was 30.0% in carriers of MMR gene mutations
(95% CI, 16.54 to 41.30; P = .07), compared
with 17.84% in the general population;
PCA incidence in Lynch syndrome families was
compared with SEER data
HR (to age 80 years) for PCA in carriers of MMR
genemutations in the combined data set was
1.99 (95% CI, 1.31 to 3.03; P = .0013).
HR, 2.48 (95% CI, 1.34 to 4.59; P = .0038)
among men age 20 to 59 years
Ryan28 Systematic review and meta-analysis that
included 23 studies (six studies with
molecular characterization and 18 risk
studies, of which 12 studies quantiﬁed risk
for PCA)
RR of PCA in carriers of MMR gene pathogenic
variants was estimated to be 3.67 (95% CI,
2.32 to 6.67).
In the sixmolecular studies, 73% (95%CI, 57%
to 85%) of PCAs in carriers of germline MMR
mutations were MMR deﬁcient.
Rosty29 32 PCA cases with germline MMR gene
mutations fromColon Cancer Family Registry
RR of PCA was highest in carriers of MSH2
mutations (RR, 5.8; 95% CI, 2.6 to 20.9)
Loss of MMR protein expression by IHC was
observed in 22 tumors (69%); the pattern of
loss of protein expression was 100%
concordant with the germline mutation.
RR of PCA inMLH1mutation carriers: 1.7; 95%
CI, 1.1 to 6.7
RR of PCA inMSH6mutation carriers: 1.3; 95%
CI, 1.1 to 5.3
Abbreviations: HR, hazard ratio; IHC: immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; PCA, prostate cancer; RR, relative risk; SIR,
standardized incidence ratio.
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